InMed Pharmaceuticals Inc. (INM) Balance Sheet
INM balance sheet, FY2026
June 30, 2026 · U.S. dollars$3.0M assets = $2.0M liabilities + $1.1M equity
Both columns are drawn to the same scale: what INM owns equals what it owes plus shareholders’ equity. Hover a block for its value.
INM financial health
Descriptive bands, not a rating. Fiscal FY2026.
INM balance sheet trends, FY2025–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $21.2MFY2025 | $3.0MFY2026 | −85.7%/yr | |
| Total liabilities | $2.9MFY2025 | $2.0MFY2026 | −33.1%/yr | |
| Shareholders’ equity | $18.3MFY2025 | $1.1MFY2026 | −94.1%/yr | |
| Cash & short-term investments | $15.1MFY2025 | $2.2MFY2026 | −85.2%/yr | |
| Working capital | $15.0MFY2025 | $721,646FY2026 | −$14.3M | |
| Current ratio | 6.99FY2025 | 1.37FY2026 | −5.62 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
INM assets
INM liabilities and equity
INM debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
INM balance sheet
| FY2026 | FY2025 | |
|---|---|---|
| Assets | ||
| Cash & short-term investments | $2.2M | $15.1M |
| Cash & equivalents | $2.2M | $15.1M |
| Short-term investments | $39,592 | $43,565 |
| Receivables | $0 | $633,671 |
| Inventory | $0 | $1.3M |
| Other current assets | $446,963 | $497,467 |
| Total current assets | $2.7M | $17.5M |
| Property, plant & equipment (net) | $221.0M | $1.4M |
| Goodwill & intangible assets | $0 | $2.2M |
| Long-term investments | $0 | $0 |
| Other non-current assets | $0 | $136,244 |
| Total assets | $3.0M | $21.2M |
| Liabilities | ||
| Accounts payable | $927,170 | $504,292 |
| Short-term debt | — | $593,347 |
| Total current liabilities | $2.0M | $2.5M |
| Long-term debt | $0 | $0 |
| Lease obligations | $0 | $741,262 |
| Other long-term liabilities | $0 | $416,569 |
| Total liabilities | $2.0M | $2.9M |
| Shareholders' equity | ||
| Common stock & paid-in capital | $94.3M | $124.3M |
| Retained earnings (deficit) | −$130.2M | −$159.7M |
| Accumulated other comprehensive income | $128,569 | $175,166 |
| Total shareholders' equity | $1.1M | $18.3M |
| Key figures | ||
| Total debt | — | $1.0M |
| Net cash (debt) | — | $14.1M |
| Working capital | $721,646 | $15.0M |
| Tangible book value | $1.1M | $16.1M |
| Book value per share | $0.26 | — |
| Shares outstanding | 4.2M | — |
| Current ratio | 1.37 | 6.99 |
| Quick ratio | 1.14 | 6.27 |
| Debt / equity | — | 0.06 |
| Equity / assets | 35.5% | 86.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & short-term investments | $2.2M | $5.2M | $9.6M | $13.0M | $15.1M | $6.7M | $4.9M |
| Cash & equivalents | $2.2M | $5.2M | $9.5M | $13.0M | $15.1M | $6.7M | $4.9M |
| Short-term investments | $39,592 | $41,625 | $58,574 | $59,636 | $43,565 | $40,581 | $40.8M |
| Receivables | $0 | $0 | $251,054 | $479,046 | $633,671 | $523,806 | $377,597 |
| Inventory | $0 | $0 | $947.9M | $1.2M | $1.3M | $1.2M | $1.6M |
| Other current assets | $446,963 | $1.7M | $0 | $327,223 | $497,467 | $781,059 | $984,766 |
| Total current assets | $2.7M | $6.9M | $12.1M | $15.1M | $17.5M | $9.1M | $7.9M |
| Property, plant & equipment (net) | $221.0M | $642,884 | $764.3M | $1.2M | $1.4M | $1.6M | $1.8M |
| Goodwill & intangible assets | $0 | $1.5M | $1.54B | $2.2M | $2.2M | $2.4M | $2.4M |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $104,368 | $0 | $139,475 | $136,244 | $142,413 | $143,811 |
| Total assets | $3.0M | $9.1M | $15.4M | $18.6M | $21.2M | $13.2M | $12.2M |
| Liabilities | |||||||
| Accounts payable | $927,170 | $225,051 | $228,805 | $514,778 | $504,292 | $797,232 | $826,273 |
| Short-term debt | — | $389,381 | $560,176 | $592,432 | $593,347 | $611,294 | $603,582 |
| Total current liabilities | $2.0M | $2.2M | $2.0M | $2.2M | $2.5M | $2.6M | $2.6M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $0 | $420,147 | $531,949 | $640,243 | $741,262 | $848,594 | $948,959 |
| Other long-term liabilities | $0 | $30,765 | $169,963 | $300,533 | $416,569 | $597,196 | $761,106 |
| Total liabilities | $2.0M | $2.2M | $2.2M | $2.5M | $2.9M | $3.2M | $3.3M |
| Shareholders' equity | |||||||
| Common stock & paid-in capital | $94.3M | $92.6M | $126.3M | $128.0M | $124.3M | $124.5M | $121.6M |
| Retained earnings (deficit) | −$130.2M | −$124.0M | −$166.0M | −$165.9M | −$159.7M | −$164.4M | −$163.0M |
| Accumulated other comprehensive income | $128,569 | $128,568 | $176,412 | $179,319 | $175,166 | $183,096 | $184,893 |
| Total shareholders' equity | $1.1M | $6.9M | $13.2M | $16.2M | $18.3M | $10.0M | $8.9M |
| Key figures | |||||||
| Total debt | — | $420,147 | $730,137 | $892,966 | $1.0M | $1.2M | $1.4M |
| Net cash (debt) | — | $4.8M | $8.9M | $12.1M | $14.1M | $5.5M | $3.6M |
| Working capital | $721,646 | $4.7M | $10.0M | $12.9M | $15.0M | $6.5M | $5.3M |
| Tangible book value | $1.1M | $5.4M | −$1.53B | $14.0M | $16.1M | $7.6M | $6.4M |
| Book value per share | $0.25 | $1.70 | $3.33 | $4.09 | $9.14 | — | — |
| Shares outstanding | 4.4M | 4.0M | 4.0M | 4.0M | 2.0M | — | — |
| Current ratio | 1.37 | 3.11 | 5.94 | 6.95 | 6.99 | 3.49 | 3.05 |
| Quick ratio | 1.14 | 2.35 | 4.85 | 6.22 | 6.27 | 2.74 | 2.06 |
| Debt / equity | — | 0.06 | 0.06 | 0.06 | 0.06 | 0.12 | 0.15 |
| Equity / assets | 35.5% | 75.5% | 85.7% | 86.7% | 86.2% | 75.7% | 72.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed September 9, 2026); data from EODHD.
INM financial position
At the end of fiscal 2026 (June 30, 2026), InMed Pharmaceuticals had total assets of $3.0 million (down 85.7% from a year earlier), total liabilities of $2.0 million and shareholders' equity of $1.1 million. Its current ratio was 1.37.
Related: INM income statement, INM cash flow statement, INM key metrics. See the INM stock overview for the latest quote and news.
INM balance sheet FAQ
What are InMed Pharmaceuticals's total assets?
InMed Pharmaceuticals reported total assets of $3.0 million at the end of fiscal 2026 (June 30, 2026), compared with $21.2 million a year earlier.
How much cash does InMed Pharmaceuticals have?
InMed Pharmaceuticals held $2.2 million in cash and short-term investments at the end of fiscal 2026.
What is InMed Pharmaceuticals's book value?
InMed Pharmaceuticals's shareholders' equity (book value) was $1.1 million at the end of fiscal 2026, or $0.26 per share.
What is InMed Pharmaceuticals's current ratio?
InMed Pharmaceuticals had current assets of $2.7 million and current liabilities of $2.0 million, a current ratio of 1.37 (it can cover its short-term obligations).